Table 1.
Gene | FC | 95% CI | p | q |
---|---|---|---|---|
FLJ36840 | 0.80 | 0.75–0.86 | 2.80E-06 | 0.006 |
FAM46C | 1.24 | 1.16–1.33 | 3.10E-06 | 0.006 |
KLF6 | 1.28 | 1.19–1.39 | 3.80E-06 | 0.006 |
B4GALT6 | 0.82 | 0.76–0.88 | 1.30E-05 | 0.015 |
NUDT9P1 | 0.76 | 0.69–0.85 | 3.20E-05 | 0.028 |
SNORD12C | 1.22 | 1.13–1.32 | 4.60E-05 | 0.036 |
MIRLET7E | 1.23 | 1.13–1.34 | 0.0001 | 0.054 |
MYO15B | 1.21 | 1.12–1.31 | 0.0001 | 0.055 |
SRSF6 | 1.18 | 1.10–1.27 | 0.0001 | 0.085 |
LINC01152 | 0.80 | 0.72–0.88 | 0.0002 | 0.113 |
ZNF493 | 0.84 | 0.77–0.91 | 0.0002 | 0.113 |
ZNF429 | 0.81 | 0.74–0.89 | 0.0003 | 0.114 |
CETN3 | 0.78 | 0.70–0.88 | 0.0003 | 0.114 |
NEDD1 | 0.86 | 0.81–0.92 | 0.0003 | 0.114 |
PSG6 | 0.86 | 0.80–0.92 | 0.0003 | 0.114 |
ZNF667-AS1 | 1.25 | 1.13–1.40 | 0.0003 | 0.114 |
PRRX1 | 0.84 | 0.77–0.91 | 0.0003 | 0.114 |
ZBED8 | 0.78 | 0.69–0.87 | 0.0003 | 0.117 |
ATF4 | 1.18 | 1.09–1.29 | 0.0004 | 0.137 |
ZNF724P | 0.83 | 0.76–0.91 | 0.0005 | 0.156 |
TRIB1 | 1.16 | 1.08–1.26 | 0.0005 | 0.165 |
IMPAD1 | 0.82 | 0.74–0.90 | 0.0005 | 0.165 |
CR1L | 0.84 | 0.77–0.92 | 0.0006 | 0.17 |
LOC100131860 | 0.81 | 0.73–0.90 | 0.0006 | 0.17 |
LDHC | 1.17 | 1.08–1.26 | 0.0006 | 0.17 |
SNORA19 | 1.20 | 1.09–1.32 | 0.0006 | 0.171 |
MIR30E | 0.81 | 0.72–0.90 | 0.0007 | 0.172 |
FBXO9 | 0.82 | 0.73–0.91 | 0.0008 | 0.189 |
SNORD59B | 1.33 | 1.15.1–54 | 0.0008 | 0.189 |
CI, confidence interval; FC, fold change. Linear FCs were calculated as FC = 2^logFC using the estimates of the log2-fold-change corresponding to the effect of lithium treatment provided by limma. The significance threshold was set at q < 0.2 at this step.
Genes reported in bold were also found to be associated with lithium response in the genotyped dataset.